Head-to-head evidence

BCMA CAR-NK (Hrain) vs Idecabtagene vicleucel

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

💬 Discuss in AI Terminal →

Multiple Myeloma

Shared mechanism: BCMA · full Multiple Myeloma pipeline

BCMA CAR-NK (Hrain)

Developed by Hrain Biotechnology Co., Ltd.

Phase 1/2 in Multiple Myelomacell therapy (allogeneic BCMA-targeted CAR-NK)

Weak signal

NCT05008536 · Phase 1 · status unknown

This was an open-label, single-arm study with no randomization, no blinding, and no comparator arm, in only 27 participants. Results have not been posted yet. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.)

Unlock with Research ↗

Idecabtagene vicleucel

Marketed by Bristol-Myers Squibb

Approved in Multiple Myelomacell therapy (autologous CAR-T)

Reliable signal

NCT03651128 · Phase 3 · completed

Randomized, open-label Phase 3 trial (n=386) demonstrating significant improvement in PFS vs standard regimens in relapsed/refractory multiple myeloma (NEJM 2023).

Next expected readout: May 2027 · NCT05393804 (registry estimate)

Unlock with Research ↗

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BCMA CAR-NK (Hrain)'s landscape · Idecabtagene vicleucel's landscape